CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS

Lobbying for NOVARTIS · Bio-pharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 20, 2026

Bills named in this filing 1

Lobbying activity 2

Trade (domestic/foreign)

Pharmaceutical market competition

Health Issues

Support for H.R. 1672 - Maintaining Investments in New Innovation Act (MINI Act)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.